Fig. 2 –
Selected glycosaminoglycan properties in plasma samples in the discovery set, comprising 38% of the current cohort (RCC 67, healthy 19) and two historical cohorts from Sweden (RCC 26, healthy 20) and Italy (RCC 23, healthy 5) [14]; see also Table 3. RCC = renal cell carcinoma; CS = chondroitin sulfate; HS = heparan sulfate; tot = total.